© 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8:87-93 Impact of age on clinical outcomes after everolimus-eluting and paclitaxel-eluting.

Slides:



Advertisements
Similar presentations
© 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8: Five-year clinical follow-up of unprotected left main bifurcation lesion.
Advertisements

Children Aged 5 to
MAIN-COMPARE Study Stents versus Coronary-Artery Bypass Grafting for Left Main Coronary Artery Disease.
Safety and Efficacy of DES in Women: An Individual Patient-Level Pooled Analysis of 26 Randomized Trials Including 11,557 Women Roxana Mehran, MD, FESC,
© 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8: Percutaneous, transendocardial injection of bone marrow-derived mononuclear.
© 2012 EuroIntervention. All rights reserved. EuroInterv.2007;3: \'Fused-Gold\' vs. \'Bare\' stainless steel NIRflex stents of the same geometric.
1 Financial Mathematics Clicker review session, Final.
Genomics Commercialization Glen Schuler Managing Director, Industry Liaison Office University of Saskatchewan.
I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=
I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.
© 2012 EuroIntervention. All rights reserved. EuroIntervention 2011;7: Correlation between fractional flow reserve and intravascular ultrasound.
© 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8: Comparison of intravascular ultrasound versus angiography-guided drug-eluting.
BURZOTTA F. 1, PAN M. 2 (CO-FIRST AUTHOR), TRANI C. 1, MEDINA A. 3, SUÀREZ DE LEZO J. 2, NICCOLI G. 1, ROMERO M. 2, PORTO I. 1, MAZUELOS F. 2, LEONE A.M.
© 2012 EuroIntervention. All rights reserved. EuroIntervention 2009;5: A comparison of patient characteristics and 30-day mortality outcomes after.
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with severe chronic systolic.
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
8.1.4 Can it still be factored? Factoring Completely I can factor out a common factor.
© 2012 EuroIntervention. All rights reserved. EuroIntervention 2011;6: First-in-man evaluation of intravascular optical frequency domain imaging.
PLATINUM A Prospective, Randomized, Investigation of a Novel Platinum Chromium Everolimus-Eluting Coronary Stent: The PLATINUM Trial Objective To evaluate.
Not for distribution in the U.S. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved.
Rapamycin- and Paclitaxel-Eluting Stents With Identical Biodegradable Polymeric Coating and Design Trial Presented at The American College of Cardiology.
AICT 2010-Athens Interventional Cardiovascular Therapeutics XI 8-9 OCTOBER 2010 Divani Caravel Hotel, Αthens EARLY CLINICAL OUTCOMES AFTER PROMUS ELEMENT.
© 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8: published online ahead of print October 2012 Updated standardized endpoint.
© 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8: Serial greyscale and radiofrequency intravascular ultrasound assessment of.
TAXUS ATLAS Trial Presented at The EuroPCR meeting Paris, France May 2006 Presented by Dr. Mark Turco TAXUS ATLAS 9-Month Results: Evaluation of TAXUS.
PRODIGY Objective Study Design Primary Composite Endpoint
Quality of life in patients with implantable cardioverter defibrillators Author: Camelia Tănăsuc Coordinator: Professor Doctor Dan Dobreanu Coauthors:
A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.
Harmonizing Outcomes with RevascularIZatiON and Stents (HORIZONS) Trial HORIZONS Trial.
Lisette Okkels Jensen, Per Thayssen, Henrik Steen Hansen, Evald Høj Christiansen, Hans Henrik Tilsted, Lars Romer Krusell, Anton Boel Villadsen, Anders.
ISAR-CABG Objective To compare the efficacy of DES with BMS in a randomized trial powered for clinical events Sample 610 patients with de novo SVG lesions.
Clinical Trials 2015 Practical Session 2. Exercise I Normally Distributed Response Data H 0 :  = 0 H a :  =  a > 0 n=? α=0.05 (two-sided) β=0.20 
Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Incidence and Short-Term Clinical Outcomes of Small.
$1 Million $500,000 $100,000 $50,000 $25,000 $10,000 $5,000 $1,000.
Date of download: 5/31/2016 Copyright © The American College of Cardiology. All rights reserved. From: Influence of Site and Operator Characteristics on.
Journal Club Julie Shah, MD Milton S Hershey Medical Center Penn State University.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Randomized Trial of Paclitaxel- Versus Sirolimus-Eluting.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Relationship between heparin anticoagulation and.
ΟΡΓΑΝΩΣΗ ΚΑΙ ΔΙΟΙΚΗΣΗ ΕΠΙΧΕΙΡΗΣΕΩΝ 3 Ο ΜΑΘΗΜΑ. ΟΙ ΜΕΓΑΛΕΣ ΕΠΙΧΕΙΡΗΣΕΙΣ Η δημιουργία μεγάλων επιχειρήσεων είναι ένα από τα χαρακτηριστικά του 20 ου αιώνα.
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Incidence and Correlates of Drug-Eluting Stent Thrombosis.
From: Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.
Figure 1 Ischaemic endpoints
Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.
The Perfect Marriage! Ephesians 5:21-33.
European and US Guidelines
ФОНД ЗА РАЗВОЈ РЕПУБЛИКЕ СРБИЈЕ
Dual Goals for the Management of Stable Ischemic Heart Disease (SIHD)
1.
شاخصهای عملکردی بیمارستان
مدل زنجیره ای در برنامه های سلامت
فرق بین خوب وعالی فقط اندکی تلاش بیشتر است
Как да кандидатстваме по НИФ
ОПЕРАТИВНА ПРОГРАМА “ИНОВАЦИИ И КОНКУРЕНТОСПОСОБНОСТ“ „Подобряване на производствения капацитет в МСП“
'III \-\- I ', I ,, - -
STENT THROMBISIS Insights on Outcomes and Impact of DUAL ANTIPLATELET THERAPY Permanent Discontinuation SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE.
Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

“Like a Child” Luke 18:9-17 Jesus, His Spirit, His Mission
Can Drug-Coated Balloons Be a Solution for Complex Peripheral Lesions?
Solving Equations 3x+7 –7 13 –7 =.
SPIRIT diagram. SPIRIT diagram. The figure details the timing of enrollment activities, intervention allocation, and assessments of outcomes over the course.
Example Make x the subject of the formula
DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.
Primary safety endpoint
,, 'III \-\-
The patient is a 57-year-old man with a clinical diagnosis of in-stent restenosis on his left side by digital subtraction angiography and CT angiography.
My PAH Patient.
Volume 50, Issue 2, Pages iii-iv (April 2019)
U A B II III I IV 94.
Presentation transcript:

© 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8:87-93 Impact of age on clinical outcomes after everolimus-eluting and paclitaxel-eluting stent implantation: pooled analysis from the SPIRIT III and SPIRIT IV clinical trials

© 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8:87-93 Impact of age on clinical outcomes after everolimus-eluting and paclitaxel-eluting stent implantation: pooled analysis from the SPIRIT III and SPIRIT IV clinical trials

© 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8:87-93 Impact of age on clinical outcomes after everolimus-eluting and paclitaxel-eluting stent implantation: pooled analysis from the SPIRIT III and SPIRIT IV clinical trials

© 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8:87-93 Impact of age on clinical outcomes after everolimus-eluting and paclitaxel-eluting stent implantation: pooled analysis from the SPIRIT III and SPIRIT IV clinical trials

© 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8:87-93 Impact of age on clinical outcomes after everolimus-eluting and paclitaxel-eluting stent implantation: pooled analysis from the SPIRIT III and SPIRIT IV clinical trials

© 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8:87-93 Impact of age on clinical outcomes after everolimus-eluting and paclitaxel-eluting stent implantation: pooled analysis from the SPIRIT III and SPIRIT IV clinical trials

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.